Prevalance of Epilepsy in School-age Children in Erzurum

被引:0
作者
Aygun, Belkis [1 ]
Tan, Huseyin [2 ]
机构
[1] Erzurum Training & Res Hosp, Dept Pediat, Erzurum, Turkey
[2] Erzurum Training & Res Hosp, Dept Neurol, Erzurum, Turkey
来源
TRENDS IN PEDIATRICS | 2021年 / 2卷 / 03期
关键词
Epilepsy; prevalence; school-age child; ACUTE LYMPHOBLASTIC-LEUKEMIA; ANTIGEN-EXPRESSION; CLINICAL-FEATURES; PROGNOSTIC-SIGNIFICANCE; EARLY RESPONSE; CHILDHOOD; EXPERIENCE; SURVIVAL; MARKERS; IMPACT;
D O I
10.5222/TP.2021.76486
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Objective: This study aimed to investigate the prevalence of epilepsy in school children in Erzurum and compare it with prevalence studies in Turkey and worldwide. Methods: This is a cross-sectional study conducted in the center of Erzurum. From the universe formed by 74,732 students, 5,571 people were selected through the "proportionate stratified sampling method" and 4,560 (80%) of the 5,700 questionnaires distributed were collected. Based on the data obtained, 563 students were accepted as possible epilepsy cases and examined for epilepsy. Results: TOf the students participating in the study, 51.3% were female and 48.6% male. Six girls (3/1000) and 10 boys (5/1000), a total of 16 cases (4/1000) were detected to be followed -up for epilepsy. Prevalence rates were found to be 4.5/1000, 2.6/1000 and 3.6/1000 for males, females and the total population, respectively. The prevalence of active epilepsy was determined to be 4/1000, 2/1000, and 3/1000 for males, females and the sum of both, respectively. Conclusion: Epilepsy is an important health problem for our region. The prevalence of epilepsy among school -age children in Erzurum was close to the prevalence rate seen in developed countries. Febrile convulsion, low educational level and low socioeconomic level are the risk factors for epilepsy.
引用
收藏
页码:131 / 139
页数:9
相关论文
共 34 条
[1]  
Bahoush Gholamreza, 2019, Med Arch, V73, P311, DOI 10.5455/medarh.2019.73.311-315
[2]  
Barazanchi A, 2005, Bahrain Medical Bulletin, V27, P175
[3]   Revisiting the complete blood count and clinical findings at diagnosis of childhood acute lymphoblastic leukemia: 10-year experience at a single center [J].
Carlos Jaime-Perez, Jose ;
Garcia-Arellano, Gisela ;
Luis Herrera-Garza, Jose ;
Javier Marfil-Rivera, Luis ;
Gomez-Almaguer, David .
HEMATOLOGY TRANSFUSION AND CELL THERAPY, 2019, 41 (01) :57-61
[4]   Relapse of childhood acute lymphoblastic leukemia and outcomes at a reference center in Latin America: organomegaly at diagnosis is a significant clinical predictor [J].
Carlos Jaime-Perez, Jose ;
Andrea Pinzon-Uresti, Monica ;
Alberto Jimenez-Castillo, Raul ;
Esther Colunga-Pedraza, Julia ;
Gonzalez-Llano, Oscar ;
Gomez-Almaguer, David .
HEMATOLOGY, 2018, 23 (01) :1-9
[5]   Early response to chemotherapy as a prognostic factor in childhood acute lymphoblastic leukaemia: a methodological review [J].
Donadieu, J ;
Hill, C .
BRITISH JOURNAL OF HAEMATOLOGY, 2001, 115 (01) :34-45
[6]  
DREXLER HG, 1991, LEUKEMIA, V5, P637
[7]   Survival from childhood acute lymphoblastic leukaemia in West Germany: Does socio-demographic background matter? [J].
Erdmann, Friederike ;
Kaatsch, Peter ;
Zeeb, Hajo ;
Roman, Eve ;
Lightfoot, Tracy ;
Schuez, Joachim .
EUROPEAN JOURNAL OF CANCER, 2014, 50 (07) :1345-1353
[8]   Clinical features and induction outcome of childhood acute lymphoblastic leukemia in a lower/middle income population: A multi-institutional report from Pakistan [J].
Fadoo, Zehra ;
Nisar, Imran ;
Yousuf, Fatimah ;
Lakhani, Laila Saleem ;
Ashraf, Shamvil ;
Imam, Uzma ;
Zaheer, Junaid ;
Naqvi, Ahmed ;
Belgaumi, Asim .
PEDIATRIC BLOOD & CANCER, 2015, 62 (10) :1700-1708
[9]   PROGNOSTIC-SIGNIFICANCE OF MYELOID-ASSOCIATED ANTIGEN EXPRESSION ON BLAST CELLS IN CHILDREN WITH ACUTE LYMPHOBLASTIC-LEUKEMIA [J].
FINK, FM ;
KOLLER, U ;
MAYER, H ;
HAAS, OA ;
GRUMAYERPANZER, ER ;
URBAN, C ;
DENGG, K ;
MUTZ, I ;
TUCHLER, H ;
GATTERERMENZ, I ;
KNAPP, W ;
GADNER, H .
MEDICAL AND PEDIATRIC ONCOLOGY, 1993, 21 (05) :340-346
[10]  
Gaynon PS, 1997, CANCER-AM CANCER SOC, V80, P1717, DOI 10.1002/(SICI)1097-0142(19971101)80:9<1717::AID-CNCR4>3.0.CO